An anti-inflammatory drug commonly used to treat gout could significantly improve outcomes in patients with mild-to-moderate COVID-19 infections, according to research by a team led by Ralph Tripp. In a dose-range study of probenecid, researchers showed significant improvements both in preventing the transmission of COVID-19 and the speed at which symptoms cleared in patients. In comparison to other FDA-approved drugs used to treat the virus, probenecid helped clear symptoms several days faster, Tripp said. "This is a significant development," said Tripp. "It shows improvement in both virus clearance and symptom reduction." TrippBio enrolled 75 non-hospitalized patients with mild-to-moderate COVID-19. The...